

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 58856

Title: Thromboembolic Events in Metastatic Testicular Cancer Treated with Cisplatin-Based Chemotherapy

Reviewer's code: 05387032

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: United States

Author's Country/Territory: United States

Manuscript submission date: 2020-08-11

Reviewer chosen by: Li Ma

Reviewer accepted review: 2020-12-01 09:32

Reviewer performed review: 2020-12-01 10:46

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

Dear authors, Thank-you for your article and describing your experience with TEE and testicular GCTs. I have a few questions about the population, appreciating practices may vary between countries. 1. I note 6 patients had RPLND prior to chemotherapy. Why was this? 2. Is the rate of CVC related TEE higher than in other tumour groups? 3. When did the TEE occur? Earlier or later in the chemotherapy cycles? 4. Do you have any data for levels of BHCG/aFP/LDH at baseline for those who developed TEE vs those who didn't? Are they significant? 5. How many patients had an orchidectomy prior to chemotherapy/TEE? Could this have been a risk factor?